GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Thrombosis Research, Elsevier BV, Vol. 139 ( 2016-03), p. 1-9
    Type of Medium: Online Resource
    ISSN: 0049-3848
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2016
    detail.hit.zdb_id: 1500780-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Journal of Hematology & Oncology, Springer Science and Business Media LLC, Vol. 8, No. 1 ( 2015-12)
    Type of Medium: Online Resource
    ISSN: 1756-8722
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2015
    detail.hit.zdb_id: 2429631-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Thrombosis Research, Elsevier BV, Vol. 144 ( 2016-08), p. 6-11
    Type of Medium: Online Resource
    ISSN: 0049-3848
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2016
    detail.hit.zdb_id: 1500780-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 3814-3814
    Abstract: Introduction: Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) caused by the activation of donor T lymphocytes by host antigen-presenting cells and the immune-mediated inflammatory response. Epithelial cells of the skin and mucous membranes, biliary ducts, and intestinal tract crypts are the primary tissue systems damaged during the pathobiological course of GVHD. IL-35, a member of the IL-12 family of cytokines, comprising an IL-12 p35 subunit and an IL-12 p40-related protein subunit, EBV-induced gene 3 (EBI3). It is an anti-inflammatory cytokine that suppresses the immune response through the expansion of regulatory T cells and suppression of Th17 cell development (Niedbala W, et al. European journal of immunology 2007). Rapamycin (Sirolimus; RAPA), a macrolide antibiotic produced by Streptomyces hygroscopicus, has been used for the prophylaxis and treatment of several immune reactions including GVHD and solid organ rejection (Ho-Jin Shin, et al. Blood 2011). We hypothesized that IL-35 has a protective effect in aGVHD, and that its function may be increased by RAPA. Methods: We used C57BL/6 (B6, H-2b) mice as donors and (B6×DBA/2)F1 (BDF1, H-2b×d) mice as recipients to create an aGVHD model (Kuroiwa T, et al. The Journal of clinical investigation 2001). Mice were divided into five groups, including a BMT control group, aGVHD control group, aGVHD treated with IL-35 group, aGVHD treated with RAPA group and aGVHD treated with IL-35 and RAPA group. Morbidity and mortality related to aGVHD were observed, and 2 weeks after BMT, tissues from the intestine and liver were stained with hematoxylin and eosin and examined by light microscopy. To detect apoptosis in intestinal sections, a modified terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling (TUNEL) method was applied. CD4+CD25+Foxp3+ regulatory T cells were measured by flow cytometry. Quantitative RT-PCR was used to measure the production of IFN-γ, TNF-α and IL-17A in the spleen and intestine of each group of mice. We also measured platelet aggregation using a turbidimetric aggregation-monitoring device. Finally, western blotting was conducted to test the signaling pathways of IL-35. Results: Mice receivingIL-35 exhibited a higher survival rate compared with GVHD mice as well as those mice receiving RAPA. When the two drugs were given together, the survival rate was much higher than that in the other groups. The aGVHD control group had the highest morbidity rate of aGVHD, and IL-35 plus RAPA could prevent the occurrence of aGVHD. Additionally, this treatment inhibited apoptosis of intestinal epithelial cells as well as donor T-cell infiltration into the liver, thereby ameliorating the enteropathy and liver injury caused by aGVHD. The importance of the inflammatory cytokine cascade in the pathogenesis of both clinical and experimental GVHD is now well accepted. We found that IL-35 and RAPA also markedly suppressed IFN-γ, TNF-α and IL-17A expression in the intestine and liver. Because studies by other have showed that Tregs have the ability to inhibit aGVHD, we measured Tregs in serum and found that IL-35 and RAPA treatment expanded serum Tregs. We further explored the relationship between IL-35 and platelet aggregation. Platelet aggregation was high in aGVHD mice, and the ratio of platelet aggregation was inhibited by IL-35 and RAPA. Finally, we found that the phosphorylation of STAT1 and STAT4 were inhibited in GVHD mice, and thatSTAT1 and STAT4 were phosphorylated when mice were treated with IL-35. Conclusions: IL-35 may be useful for controlling aGVHD after allo-HSCT. IL-35 suppresses inflammatory cytokines and expands anti-inflammatory cells in aGVHD. IL-35 also prevents platelet aggregation in aGVHD mice, which could be helpful in treating thrombotic complications after HSCT. These results are readily translatable to the clinic in future clinical trials. IL-35 and RAPA may have potential clinical use for the prevention or treatment of aGVHD and thrombotic complications after HSCT. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 1174-1174
    Abstract: Introduction: Acute graft-versus-host disease (aGVHD) is a major limitation of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The mechanism of aGVHD has not been completely elucidated. aGVHD is primarily caused by immune responses to allogeneic disparities between the donor and recipient organs (Nakamura K, et al. Bone marrow transplantation 2005). aGVHD can also lead to thrombotic complications through endothelial damage. Following endothelial injury, inflammation triggers platelet activation and leads to enhanced expression of CD62P, which can then interact with the P-selectin glycoprotein ligand 1 receptor expressed on monocytes and mediate the rolling of monocytes on activated endothelium, facilitating platelet-leukocyte aggregation and inducing platelet thrombus formation. IL-35 is a novel anti-inflammatory cytokine that suppresses the immune response. Previous work has demonstrated that IL-35 is an anti-inflammatory cytokine that suppresses the immune response through the expansion of regulatory T cells and suppression of Th17 cell development that has a protective function in various autoimmune disorders. In this study, we hypothesized that patients with aGVHD may have increased platelet aggregation, which is associated with an increased risk of thrombus formation in aGVHD. Because the increased platelet aggregation is caused by inflammation during aGVHD, and IL-35 is a novel anti-inflammatory cytokine, IL-35 could also inhibit platelet activation and aggregation in aGVHD patients. Methods: In this study, we prospectively studied a total of 65 patients who received allo-HSCT. We measured plasma levels of IL-35 inpatients just at the onset of aGVHD. We collected time-matched samples from patients without aGVHD to serve as controls after HSCT. We also detected the levels of IL-35 in granulocyte-colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells (PBPC) and G-CSF-primed bone marrow (GBM) to explore the relationship between IL-35 levels and the occurrence of aGVHD. Then, we analyzed platelet aggregation in patients with and without aGVHD. We also added IL-35 to the plasma of these patients to test its function on platelet aggregation and platelet activation. Results: The plasma levels of IL-35 were reduced in the patients with grade III-IV aGVHD (23.46 ng/ml) compared with the patients with grade I-II aGVHD (40.26 ng/ml, p 〈 0.01) and no aGVHD (41.40 ng/ml, p 〈 0.05). Allografts from 38 patients were analyzed for IL-35 levels with respect to aGVHD. The patients were divided into either a high IL-35 group or a low IL-35 group according to the median levels of IL-35 in the patient’s GBM (28.0 pg/ml) and PBPC (53.1 pg/ml). We found that patients in the low IL-35 group demonstrated a higher cumulative incidence of aGVHD compared with patients in the high IL-35 group. In addition, patients with aGVHD have increased platelet aggregation compared with patients without aGVHD. In vitro, platelet aggregation was inhibited by IL-35 in a dose-dependent manner. The markers of platelet activation (CD62P/PAC-1) were also inhibited by IL-35. Conclusions: The results imply that IL-35 may predict the occurrence of aGVHD, as well as inhibit platelet activation and aggregation. These data suggest that IL-35 might represent a potential effective therapeutic agent against aGVHD and prevent thrombotic complications after allo-HSCT. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 432-432
    Abstract: Introduction: Prolonged isolated thrombocytopenia (PIT) represents a significant complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and is associated with an adverse patient prognosis and higher transplant-related mortality owing to a higher risk of infection events, severe (grades 3 to 4) acute graft-versus-host disease (GVHD) and chronic GVHD. PIT is defined as a peripheral platelet count less than 100×109/L without sustained anemia or leukopenia for more than 3 months after allo-HSCT (Zhang X, et al. Biol Blood Marrow Transplant, 2011). However, the underlying mechanisms remain unclear. Different kinds of functional glycoproteins are expressed on the platelet surface, with sialic acid residues at the end of their glycan. Desialylation of platelet glycoproteins has been found to be associated with accelerated platelet clearance in refrigerated platelets (Gerard Jansen AJ, et al. Blood 2012). Platelet-specific glycoprotein GPIbα,the functional subunit of the von Willebrand factor receptor, was the majorly desialylated glycoprotein; NEU1, one of the four human sialidases, was the enzyme that catalyzed GPIbα desialylation. However, few studies have focused on this mechanism in patients suffering PIT after allo-HSCT. In this study, we hypothesized that desialylation on platelet surfaces is associated with PIT after allo-HSCT. The mechanisms participating in this process may include GPIbα clustering, platelet apoptosis and phagocytosis by macrophages. Patients and methods: Blood samples were collected 90 days after allo-HSCT from 70 patients with PIT. Samples from post-transplantation patients who have normal platelet counts were taken as controls. Sialylation and desialylation were measured by detecting specific lectins via flow cytometry. Human sialidase expression was determined by immunofluorescence, flow cytometry and reverse transcription PCR. Platelet apoptosis markers were measured by flow cytometry, and macrophages stimulated from THP-1 cells were used in the phagocytosis assay. Results: We tested sialic acid residues and the desialylation markers, including β-galactose and β-N-Acetyl glucosamine, on the platelet surface, and found that platelets from PIT patients had significantly higher desialylation levels. Serum sialic acid levels were measured, and the results showed higher levels in PIT patients. Further, NEU1 was found to be over-expressed on the surface of platelets from PIT patients, and was found to be the enzyme that catalyzed the platelet surface desialylation. To further reveal the mechanism that lead to PIT, we proved that GPIbα was the desialylated glycoprotein on platelets from PIT patients. We found that GPIbα desialylation and clustering in PIT patients induced changes in the expression of Bcl-2 family protein, as a 2-fold increase in active Bax expression and a similar decrease in Bcl-XL expression were observed. Depolarization of the inner mitochondria membrane was augmented in desialylated platelets from PIT patients, indicating increased platelet apoptosis. Moreover, macrophages stimulated from the THP-1 cell line preferred to phagocytose desialylated platelets from PIT patients in vitro; this process could be blocked by the sialidase inhibitor, DANA. In the in vitrostudy, we found that dexamethasone led to a 32% decrease in phagocytosis, whereas oseltamivir, an antiviral medicine that can block sialidase from influenza virus, could also partially function on human sialidase and protect 43% of platelets from phagocytosis. In conclusion, our results demonstrate that desialylation played a role in the mechanism of prolonged isolated thrombocytopenia after allo-HSCT, most likely through platelet apoptosis induction and increased phagocytosis by macrophages in the peripheral circulation. Dexamethasone and oseltamivir could decrease platelet apoptosis and inhibit platelet phagocytosis in vitro, implying a novel potential method for treating PIT after allo-HSCT. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 2513-2513
    Abstract: Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for malignant hematological diseases, but prolonged isolated thrombocytopenia (PIT) following allo-HSCT seriously decreases patient survival after transplantation. PIT was defined as a platelet count 〈 100×109/L for more than 3 months after HSCT, recovery of all other cell counts, and no apparent cause for thrombocytopenia(Zhang XH et al, Biol Blood Marrow Transplant, 2011). Endothelial progenitor cells (EPCs) are a minor subpopulation of peripheral blood mononuclear cells with surface expression of both endothelial and stem cell (CD34) lineage antigens. These cells were able to promote vasculogenesis at sites of ischemia in vitro. Recent research has shown that EPCs inhibit platelet aggregation by secreting prostacyclin (PGI2) (Abou-Saleh et al., Circulation, 2009). However, to our knowledge, there is no research regarding the relationship between EPCs and PIT after allo-HSCT. We hypothesize that PIT after allo-HSCT is associated with an abnormal increase of EPCs, which might secret high levels of PGI2 and inhibit platelet activation and aggregation. Methods and results We enrolled 78 patients who underwent allo-HSCT in our department due of various types of hematological malignancies, of which 38 patients were suffering from PIT and 40 were matched controls. In the patients suffering from PIT after allo-HSCT, a significantly higher percentage of BM EPCs percent were found compared with the control group (0.041%±0.022% v 0.021%±0.012%, p 〈 0.05) at +3 months after allo-HSCT. However, when the PIT patients were classified into subgroups according to the PLT count at +3 month after allo-HSCT, the difference only existed in patients with lower platelet counts (PLT 〈 50 x 109/L) and controls (0.052%±0.025 v 0.021%±0.012%, p 〈 0.05), but there was no significant difference between the subgroups of PIT patients. Then, we tested whether PGI2 levels had the same tendency as the EPCs. We found that in PIT patients, the serum PGI2 levels seemed to be higher than in the control group, but the difference did not reach statistical significance (379.23±43.41 pg/ml v 234.75±38.49 pg/ml, p=0.08). However, when classified into subgroups, serum PGI2 levels of patients with lower platelet counts were significantly higher than those of the controls (433.32±76.43 pg/ml v 234.75±38.49 pg/ml, p 〈 0.05). We also measured platelet aggregation and activation in the two groups. We found that platelet aggregation and activation (measured by CD62P and PAC-1, respectively) in PIT patients were significantly lower than in the control group (PLT aggregation: 21.2%± 5.5% v 29.2% ±8.7%, p 〈 0.05; PLT activation-PAC-1: 21.6%± 7.3% v 28.7% ±8.3%, p 〈 0.05; PLT activation-CD62P: 43.7%± 8.3% v 38.9% ±9.4%, p =0.22). However, when further classified into subgroups, none of the groups showed significant differences. Conclusion Patients suffering PIT after allo-HSCT have a higher percentage of BM EPCs, higher serum PGI2 levels and lower platelet activation and aggregation. These data might lead to new insight into the mechanism of PIT following allo-HSCT, and provide a potential avenue for treatment for PIT after allo-HSCT. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Current Applied Physics, Elsevier BV, Vol. 9, No. 2 ( 2009-3), p. 324-328
    Type of Medium: Online Resource
    ISSN: 1567-1739
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2009
    detail.hit.zdb_id: 2039065-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...